Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › androgenetic alopecia

Androgenetic alopecia

Subtypes of Androgenetic alopecia

Alopecia Areata 11

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for androgenetic alopecia

24 trials tracked for androgenetic alopecia: 4 in phase 3 or 4 and 1 with published results. The most-cited published study has 14 citations.

24Trials tracked
4Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 4 Phase 2 5 Phase 1 1 Other / NA 14
  1. Phase 3 Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5% Completed · 14 cited
  2. Phase 3 Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia Completed
  3. Phase 3 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Completed
  4. Phase 3 Clinical Trial in Females for Female Pattern Hair Loss Completed
  5. Phase 2 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Completed
  6. Phase 2 Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia Completed
Show 18 more trials
  1. Phase 2 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Completed
  2. Phase 2 A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution Completed
  3. Phase 2 Topical Bimatoprost Effect on Androgen Dependent Hair Follicles Completed
  4. Phase 1 Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia Completed
  5. N/A Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19). Completed
  6. N/A A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy Completed
  7. N/A Anti-Androgen Treatment for COVID-19 Completed
  8. N/A STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia Completed
  9. N/A Treatment of Androgenetic Alopecia in Females, 9 Beam Completed
  10. N/A Efficacy Study of a Cosmetic Lotion in the Treatment of Androgenetic Alopecia in Males and Females Completed
  11. N/A Treatment of Androgenic Alopecia in Males Completed
  12. N/A Treatment of Androgenetic Alopecia in Males Completed
  13. N/A Adipose-derived SVF for Treatment of Alopecia Completed
  14. N/A The Effect of Platelet Rich Plasma on Non-scarring Alopecia Completed
  15. N/A Modulated Light Therapy in Participants With Pattern Hair Loss Completed
  16. N/A Computer-Assisted Versus Manual Hair Harvest Comparative Study Completed
  17. N/A DUS on the Prescribing Indications for CPA/EE in 5 European Countries Completed
  18. N/A Treatment of Androgenetic Alopecia in Females, 12 Beam Completed

Showing the 24 most-cited and recently-updated of 24 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Androgenetic alopecia: what the trials found

Several interventions have demonstrated statistically significant improvements in hair growth metrics for androgenetic alopecia. P-3074 showed a significant increase in the adjusted mean change from baseline in hair growth as assessed by Target Area Hair Count (TAHC) at both 12 weeks and 24 weeks (p < 0.001) 2. However, changes in Target Area Hair Width (TAHW) for this intervention did not reach statistical significance (p = 0.322) 2.

Minoxidil 5% topical foam demonstrated significant improvements in both Target Area Hair Count and Subject Assessment of Scalp Coverage (p < 0.0001) 3. Finasteride 1mg also showed statistically significant increases in Target Area Hair Count at the vertex at week 24 (p = 0.046) 4, with notable improvements observed at the 12-week mark as well.

Bimatoprost Formulation A was evaluated for safety and tolerability; trials indicated no clinically significant ECG findings and a low incidence of increased local scalp tolerability issues 10. While clinical outcome scores (SSA, IGA, GPR) were recorded for this formulation, they did not reach statistical significance in the primary reported data 9.

Recent results — preliminary, needs further review

  • TDM-105795 (0.0025%) was evaluated in a Phase 2 trial regarding Investigator's Global Assessment (IGA) scores, but results are not yet corroborated.
  • Bimatoprost Solution 1 showed varied response categories across SSA, IGA, and GPR scales in a Phase 2 study.
  • Bimatoprost demonstrated mixed results in percent changes for target area total, terminal, and vellus hair counts.

For the clinician treating this condition

  • P-3074 is associated with significant increases in Target Area Hair Count at the vertex at 12 and 24 weeks.
  • 5% Minoxidil topical foam and 1mg Finasteride are established interventions that significantly increase target area hair counts.
  • Bimatoprost Formulation A demonstrated a favorable safety profile regarding ECG findings and local scalp tolerability.

AI synthesis of 5 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase 3 trial of low-dose IL-2 versus placebo for severe alopecia areata completed in 44 patients
Dermatology Phase III
Phase 3 trial of low-dose IL-2 versus placebo for severe alopecia areata completed in 44 patients Phase 3 trial tests low-dose IL-2 for severe alopecia areata, results pending
A Phase 3, prospective, randomized, double-blind, multicenter trial compared low-dose IL-2 to placebo in 44 patients with severe alopecia ar…
A major late-stage trial testing low-dose IL-2 for severe alopecia areata has finished, but results on hair regrowth are not yet available.
CT.gov Mar 30, 2026